C4 Therapeutics (CCCC) Short Interest Ratio & Short Volume → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free CCCC Stock Alerts $6.24 -0.23 (-3.55%) (As of 04/25/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media C4 Therapeutics Short Interest DataCurrent Short Volume9,560,000 sharesPrevious Short Volume9,150,000 sharesChange Vs. Previous Month+4.48%Dollar Volume Sold Short$65.58 millionShort Interest Ratio / Days to Cover3.7Last Record DateApril 15, 2024Outstanding Shares68,600,000 sharesPercentage of Shares Shorted13.94%Today's Trading Volume1,418,152 sharesAverage Trading Volume3,597,359 sharesToday's Volume Vs. Average39% Short Selling C4 Therapeutics ? Sign up to receive the latest short interest report for C4 Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCCCC Short Interest Over TimeCCCC Days to Cover Over TimeCCCC Percentage of Float Shorted Over Time Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). C4 Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20249,560,000 shares $65.58 million +4.5%N/A3.7 $6.86 3/31/20249,150,000 shares $74.76 million +73.0%N/A2.4 $8.17 3/15/20245,290,000 shares $47.24 million +78.1%N/A1.1 $8.93 2/29/20242,970,000 shares $32.61 million -6.6%N/A0.2 $10.98 2/15/20243,180,000 shares $25.12 million -5.1%N/A0.2 $7.90 1/31/20243,350,000 shares $20.70 million -39.6%8.7%0.2 $6.18 Get the Latest News and Ratings for CCCC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20245,550,000 shares $37.74 million +22.3%14.5%0.4 $6.80 12/31/20234,540,000 shares $25.65 million -44.0%10.8%0.3 $5.65 12/15/20238,100,000 shares $40.10 million +330.9%19.3%0.7 $4.95 11/30/20231,880,000 shares $3.06 million -3.6%4.5%3.4 $1.63 11/15/20231,950,000 shares $3.51 million +2.1%4.7%4.1 $1.80 10/31/20231,910,000 shares $2.85 million +4.4%4.6%3.9 $1.49 10/15/20231,830,000 shares $3.64 million -19.0%4.6%3.8 $1.99 9/30/20232,260,000 shares $4.20 million -5.0%5.6%5.2 $1.86 9/15/20232,380,000 shares $5.31 million +14.4%5.9%2.4 $2.23 8/31/20232,080,000 shares $6.03 million +9.5%5.2%1.9 $2.90 8/15/20231,900,000 shares $6.42 million -10.0%4.7%1.6 $3.38 7/31/20232,110,000 shares $8.21 million -5.8%5.3%1.7 $3.89 7/15/20232,240,000 shares $7.50 million -8.9%5.6%1.8 $3.35 6/30/20232,460,000 shares $6.77 million -26.4%6.1%2 $2.75 6/15/20233,340,000 shares $12.06 million +2.8%8.3%5.1 $3.61 5/31/20233,250,000 shares $11.02 million +12.1%8.1%5.4 $3.39 5/15/20232,900,000 shares $9.69 million +0.7%7.2%5.2 $3.34 4/30/20232,880,000 shares $8.70 million +1.8%7.0%5 $3.02 4/15/20232,830,000 shares $9.48 million +7.6%6.9%4.9 $3.35 3/31/20232,630,000 shares $8.26 million -9.9%6.5%4.5 $3.14 3/15/20232,920,000 shares $12.59 million -10.2%7.2%5.1 $4.31 2/28/20233,250,000 shares $17.13 million +0.9%8.0%6.3 $5.27 2/15/20233,220,000 shares $18.58 million -12.5%7.9%6.1 $5.77 1/31/20233,680,000 shares $28.67 million +2.8%9.0%7 $7.79 1/15/20233,580,000 shares $30.57 million +2.0%8.8%7.8 $8.54 12/30/20223,510,000 shares $20.71 million -3.6%8.6%7.8 $5.90 12/15/20223,640,000 shares $29.48 million +0.3%8.9%8 $8.10 11/30/20223,630,000 shares $31.11 million -8.1%8.9%7.5 $8.57 11/15/20223,950,000 shares $38.39 million -19.1%9.7%8.5 $9.72 10/31/20224,880,000 shares $46.95 million -1.2%11.9%11.4 $9.62 10/15/20224,940,000 shares $39.32 million -2.0%12.9%12.1 $7.96 9/30/20225,040,000 shares $44.20 million +11.0%13.2%11.9 $8.77 9/15/20224,540,000 shares $51.57 million -6.8%11.8%9.8 $11.36 8/31/20224,870,000 shares $49.09 million -5.1%12.7%9.9 $10.08“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). CCCC Short Interest - Frequently Asked Questions What is C4 Therapeutics' current short interest? Short interest is the volume of C4 Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 9,560,000 shares of CCCC short. Learn More on C4 Therapeutics' current short interest. What is a good short interest ratio for C4 Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CCCC shares currently have a short interest ratio of 4.0. Learn More on C4 Therapeutics's short interest ratio. Which institutional investors are shorting C4 Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of C4 Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is C4 Therapeutics' short interest increasing or decreasing? C4 Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 9,560,000 shares, an increase of 4.5% from the previous total of 9,150,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does C4 Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to C4 Therapeutics: Taysha Gene Therapies, Inc. (8.59%), Humacyte, Inc. (4.38%), Editas Medicine, Inc. (22.81%), Alector, Inc. (9.48%), Fate Therapeutics, Inc. (16.62%), Exscientia plc (3.70%), Voyager Therapeutics, Inc. (6.37%), Valneva SE (0.07%), Lexeo Therapeutics, Inc. (5.21%), Replimune Group, Inc. (18.75%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short C4 Therapeutics stock? Short selling CCCC is an investing strategy that aims to generate trading profit from C4 Therapeutics as its price is falling. CCCC shares are trading down $0.23 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against C4 Therapeutics? A short squeeze for C4 Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CCCC, which in turn drives the price of the stock up even further. How often is C4 Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CCCC, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: TSHA Short Interest HUMA Short Interest EDIT Short Interest ALEC Short Interest FATE Short Interest EXAI Short Interest VYGR Short Interest VALN Short Interest LXEO Short Interest REPL Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CCCC) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings